[Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer].

Revista medica del Instituto Mexicano del Seguro Social Pub Date : 2024-01-08 DOI:10.5281/zenodo.10278131

Yesica Guadalupe Barboza-García, Lázaro Ramírez-Balderrama, Mario Murguía-Pérez, Martha Alicia Hernández-González, Isette Yunue Landeros-Navarro

{"title":"[Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer].","authors":"Yesica Guadalupe Barboza-García, Lázaro Ramírez-Balderrama, Mario Murguía-Pérez, Martha Alicia Hernández-González, Isette Yunue Landeros-Navarro","doi":"10.5281/zenodo.10278131","DOIUrl":null,"url":null,"abstract":"Background: Primary breast tumors with neuroendocrine (NE) differentiation are a heterogeneous tumor group with diversity of biological behavior, with poorly defined prevalence and prognosis.Objective: To evaluate the chromogranin, synaptophysin, CD56, INSM1 markers expression prevalence and the association between NE differentiation and tumor molecular type.Material and methods: Observational, cross-sectional study which included 110 breast tissue samples with primary invasive carcinoma. Immunohistochemistry was performed for chromogranin, synaptophysin, CD56 and INMS1 markers. NE differentiation was considered with 10-90% positive cells, and NE tumor with > 90% positive cells.Results: 26.3% showed neuroendocrine differentiation. Out of these, 48.2% were luminal-A type, 24.1% luminal-B, 11.5% HER2neu, 17.2% triple-negative; 1.8% were NE tumors. Tumors were marker positive, and out of these to chromogranin in 24.5%, synaptophysin in 28.2%, CD56 in 2.7%, INSM1 in 16.4%. Synaptophysin was expressed in 17.3% luminal-A type, 6.4% luminal-B, 0.9% HER2neu, 3.6% triple-negative. NE differentiation showed association with synaptophysin expression (r = 0.586, p = 0.0001).Conclusion: The NE differentiation prevalence was 26.3% in primary invasive breast cancers, with luminal-A molecular type predominance.","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.10278131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Primary breast tumors with neuroendocrine (NE) differentiation are a heterogeneous tumor group with diversity of biological behavior, with poorly defined prevalence and prognosis.

Objective: To evaluate the chromogranin, synaptophysin, CD56, INSM1 markers expression prevalence and the association between NE differentiation and tumor molecular type.

Material and methods: Observational, cross-sectional study which included 110 breast tissue samples with primary invasive carcinoma. Immunohistochemistry was performed for chromogranin, synaptophysin, CD56 and INMS1 markers. NE differentiation was considered with 10-90% positive cells, and NE tumor with > 90% positive cells.

Results: 26.3% showed neuroendocrine differentiation. Out of these, 48.2% were luminal-A type, 24.1% luminal-B, 11.5% HER2neu, 17.2% triple-negative; 1.8% were NE tumors. Tumors were marker positive, and out of these to chromogranin in 24.5%, synaptophysin in 28.2%, CD56 in 2.7%, INSM1 in 16.4%. Synaptophysin was expressed in 17.3% luminal-A type, 6.4% luminal-B, 0.9% HER2neu, 3.6% triple-negative. NE differentiation showed association with synaptophysin expression (r = 0.586, p = 0.0001).

Conclusion: The NE differentiation prevalence was 26.3% in primary invasive breast cancers, with luminal-A molecular type predominance.

查看原文本刊更多论文

[三阴性、管腔 A 型、管腔 B 型和 HER2neu 型乳腺癌中的神经内分泌表达标记]。

背景：具有神经内分泌（NE）分化的原发性乳腺肿瘤是一种异质性肿瘤，其生物学行为具有多样性，其发病率和预后尚未明确：具有神经内分泌（NE）分化的原发性乳腺肿瘤是一种异质性肿瘤，其生物学行为具有多样性，其发病率和预后尚不明确：材料与方法：观察性横断面研究：观察性横断面研究，包括 110 例原发性浸润癌乳腺组织样本。对嗜铬粒蛋白、突触素、CD56和INMS1标记物进行免疫组化。10%-90%的阳性细胞为神经内分泌分化，大于 90% 的阳性细胞为神经内分泌肿瘤。其中，48.2%为管腔A型，24.1%为管腔B型，11.5%为HER2neu，17.2%为三阴性；1.8%为NE型肿瘤。肿瘤标记物阳性，其中嗜铬粒蛋白阳性占 24.5%，突触素阳性占 28.2%，CD56 阳性占 2.7%，INSM1 阳性占 16.4%。17.3%的管腔A型、6.4%的管腔B型、0.9%的HER2neu型和3.6%的三阴型均表达突触素。NE分化与突触素表达相关（r = 0.586，p = 0.0001）：结论：NE分化在原发性浸润性乳腺癌中的发生率为26.3%，其中以腔隙A型分子为主。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista medica del Instituto Mexicano del Seguro Social

自引率

0.00%

发文量